Genetic and Epigenetic control of Normal and Malignant Hematopoiesis

Essential oncogenes and oncogenics programs, such as MYC, control metabolic gene expression in leukemic cells and induce metabolic shift or reprogramming during transformation and progression of the disease. Conversely, several epigenetic regulators depend on metabolic intermediates to perform their catalytic functions and metabolic dysregulations impact on gene expression programs in leukemic cells. Understanding this interplay could help identify novel vulnerabilities in leukemic cells. In collaboration with Puissant Lab we deploy state of the art in vivo and in vitro models combined with multi-omic characterizations to explore and decipher these intricate mechanisms.

With the advent of massively parallel sequencing and development of many multi-omics techniques, cancer research relies more and more on state of the art molecular biology and bionformatics analyses not easily accessible to regular biologists. Our team helps researcher design and perform classical omics techniques such as RNA-seq, scRNA-seq, ChIP-seq, ATAC-seq and high throughput screening using CRISPR/Cas9 or shRNA and designs standardized bioinformatics analysis pipelines to help researchers explore their data.